Hiroki Kato
Papers
1
Total Citations
1
H-Index
1
About
Hiroki Kato is a surgical oncologist and urological researcher whose work centers on the treatment of muscle-invasive bladder cancer (MIBC), with a particular focus on optimizing neoadjuvant chemotherapy protocols and minimally invasive surgical techniques. His research addresses one of the most clinically challenging aspects of cisplatin-based treatment: balancing therapeutic efficacy against the risk of nephrotoxicity in patients undergoing radical cystectomy. In his notable 2025 study, Kato investigated the significance of split-dose cisplatin neoadjuvant chemotherapy combined with robotic-assisted radical cystectomy, offering a pragmatic solution for patients whose renal function may be compromised by standard cisplatin administration. This work highlights his commitment to expanding cisplatin eligibility without sacrificing oncological outcomes, a meaningful advance for a patient population with limited treatment alternatives. Though early in its citation trajectory — currently accumulating 1 citation — the research addresses a timely and underserved clinical question. Kato's contributions reflect a broader effort to integrate precision chemotherapy dosing with state-of-the-art robotic surgery, positioning him as an emerging voice in uro-oncological innovation with potential to meaningfully influence future MIBC treatment guidelines.
Research Focus
Key Achievements
Top Papers
- 1